ZA931470B - A pharmaceutical composition containing a defined lipid system. - Google Patents

A pharmaceutical composition containing a defined lipid system.

Info

Publication number
ZA931470B
ZA931470B ZA931470A ZA931470A ZA931470B ZA 931470 B ZA931470 B ZA 931470B ZA 931470 A ZA931470 A ZA 931470A ZA 931470 A ZA931470 A ZA 931470A ZA 931470 B ZA931470 B ZA 931470B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
composition containing
lipid system
lipid
defined lipid
Prior art date
Application number
ZA931470A
Other languages
English (en)
Inventor
Hakan Nyqvist
Monica Einarsson
Christer Mattsson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of ZA931470B publication Critical patent/ZA931470B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA931470A 1992-03-27 1993-03-02 A pharmaceutical composition containing a defined lipid system. ZA931470B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200951A SE9200951D0 (sv) 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system

Publications (1)

Publication Number Publication Date
ZA931470B true ZA931470B (en) 1993-09-23

Family

ID=20385757

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931470A ZA931470B (en) 1992-03-27 1993-03-02 A pharmaceutical composition containing a defined lipid system.

Country Status (23)

Country Link
US (1) US5626869A (cs)
EP (1) EP0591492B1 (cs)
JP (1) JP3577312B2 (cs)
KR (1) KR100243921B1 (cs)
AT (1) ATE165971T1 (cs)
AU (1) AU3912493A (cs)
CA (1) CA2102494C (cs)
CZ (1) CZ285672B6 (cs)
DE (1) DE69318503T2 (cs)
DK (1) DK0591492T3 (cs)
ES (1) ES2116447T3 (cs)
FI (1) FI110842B (cs)
HU (1) HU219240B (cs)
IL (1) IL105017A (cs)
MX (1) MX9301716A (cs)
NO (1) NO305537B1 (cs)
NZ (1) NZ251488A (cs)
PL (1) PL172896B1 (cs)
RU (1) RU2128505C1 (cs)
SE (1) SE9200951D0 (cs)
SK (1) SK280494B6 (cs)
WO (1) WO1993019737A1 (cs)
ZA (1) ZA931470B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7556827B1 (en) 1999-08-06 2009-07-07 Max-Delbrück-Centrum-für Molekulare Medizin Implantable active ingredient depot
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
FR2803202B1 (fr) * 2000-01-03 2004-04-16 Capsulis Compositions pharmaceutiques destinees a une adminstration par voie orale
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US9308220B2 (en) * 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
JP2005523249A (ja) * 2002-01-09 2005-08-04 エンズレル インコーポレイテッド 多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20070172517A1 (en) * 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
US9303263B2 (en) 2013-03-01 2016-04-05 Vivonics, Inc. Aptamers that bind CD271
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのｍＲＮＡ療法
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
WO2015184259A1 (en) 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
WO2016196282A1 (en) 2015-05-29 2016-12-08 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
KR102950141B1 (ko) 2018-08-24 2026-04-07 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
EP4031662A1 (en) 2019-09-20 2022-07-27 Translate Bio, Inc. Mrna encoding engineered cftr
WO2021081469A2 (en) 2019-10-25 2021-04-29 The Johns Hopkins University Light-inducible crispr/cas9 system for genome editing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
JPS607934A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
AU604288B2 (en) * 1987-01-26 1990-12-13 Vestar, Inc. Phospholipid delivery vehicle for aqueous-insoluble active ingredients
SE9003100D0 (sv) * 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system

Also Published As

Publication number Publication date
WO1993019737A1 (en) 1993-10-14
MX9301716A (es) 1994-01-31
ATE165971T1 (de) 1998-05-15
SE9200951D0 (sv) 1992-03-27
NO305537B1 (no) 1999-06-21
HUT70405A (en) 1995-10-30
EP0591492A1 (en) 1994-04-13
NZ251488A (en) 1996-03-26
DE69318503T2 (de) 1998-11-05
AU3912493A (en) 1993-11-08
DE69318503D1 (de) 1998-06-18
JP3577312B2 (ja) 2004-10-13
HU9303357D0 (en) 1994-03-28
NO934284L (no) 1993-11-26
IL105017A0 (en) 1993-07-08
IL105017A (en) 1999-12-22
JPH06508155A (ja) 1994-09-14
PL172896B1 (pl) 1997-12-31
CA2102494C (en) 2008-03-18
HU219240B (en) 2001-03-28
US5626869A (en) 1997-05-06
CA2102494A1 (en) 1993-09-28
NO934284D0 (no) 1993-11-26
CZ285672B6 (cs) 1999-10-13
DK0591492T3 (da) 1999-02-15
KR100243921B1 (ko) 2000-03-02
RU2128505C1 (ru) 1999-04-10
FI935273L (fi) 1993-11-26
EP0591492B1 (en) 1998-05-13
CZ247793A3 (en) 1994-07-13
FI110842B (fi) 2003-04-15
SK132293A3 (en) 1994-07-06
ES2116447T3 (es) 1998-07-16
FI935273A0 (fi) 1993-11-26
SK280494B6 (sk) 2000-03-13

Similar Documents

Publication Publication Date Title
ZA931470B (en) A pharmaceutical composition containing a defined lipid system.
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
TR200003666T2 (tr) Akut bir astım vakasının önlenmesi , tedavisi için formoterol
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
RU93058379A (ru) Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение
MY115339A (en) Compositions containing micronized nebivolol
CS653586A3 (en) Pharmaceutical containing 7-isopropoxyisoflavone
EP0902789A4 (cs)
DK0642344T3 (da) Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
LT96093A (en) The active ingredient of pharmaceutical composition for treating aphtae and stomatitis
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ES8801267A1 (es) Procedimiento para preparar derivados de isoquinolinona
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
FR2685204B1 (fr) Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.
IT1270976B (it) Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica, loro uso e composizioni farmaceutiche che li contengono
ITMI920214A0 (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina
IL129891A0 (en) New analogues of camptothecin their use as medicaments and the pharmaceutical compositions containing them